Surgical downstaging and neo-adjuvant therapy in metastatic
colorectal carcinoma with irinotecan drug-eluting beads: a
multi-institutional study

J 2010

Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study

BOWER, M.; T. METZGER; K. ROBBINS; D. TOMALTY; Vlastimil VÁLEK et al.

Základní údaje

Originální název

Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study

Autoři

BOWER, M.; T. METZGER; K. ROBBINS; D. TOMALTY; Vlastimil VÁLEK ; Jaroslav BOUDNÝ; Tomáš ANDRAŠINA; C. TATUM a RC. MARTIN

Vydání

HPB (Oxford), 2010, 1365-182X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.285

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/10:00051437

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1111/j.1477-2574.2009.00117.x

UT WoS

000286434900005

Klíčová slova anglicky

metastatic colon cancer; liver directed therapy; chemoembolization; irinotecan

Změněno: 11. 1. 2012 20:49, MUDr. Tomáš Andrašina, Ph.D.

Anotace

V originále

Background: Neoadjuvant chemotherapy for potentially resectable metastatic colorectal cancer (MCC) is becoming a more common treatment algorithm. The aim of the present study was to evaluate the efficacy of precision hepatic arterial Irinotecan therapy in unresectable MCC. Methods: An open-label, multi-centre, multi-national single arm study of MCC patients, who received hepatic arterial irinotecan. Primary endpoints were safety, tolerance and metastatic tumour resection. Results: Fifty-five patients with metastatic colorectal to the liver underwent a total of 90 hepatic arterial irinotecan treatments. The extent of liver involvement was <25% in 75% of the patients (n = 41), between 26 and 50% in 15% of the patients (n = 11) and >50% in 10% of the patients (n = 24). The median number of hepatic lesions was four (range 1-20), with a median total size of all target lesions of 9 cm (range 5.5-28 cm) with 50% of patients having bilobar tumour distribution. The median number of irinotecan treatments was two (range 1-5). The median treatment dose was 100 mg (range 100-200) with a median total hepatic treatment of 200 mg (range 200-650). The majority of treatments (86%) were performed as lobar infusion treatments, and 30% of patients were treated with concurrent simultaneous chemotherapy. Eleven (20%) patients demonstrated significant response and downstage of their disease or demonstrated stable disease without extra-hepatic disease progression allowing resection, ablation or resection and ablation. There were no post-operative deaths. Post-operative complications morbidity occurred in 18% of patients, with none of them hepatic related. Non-tumorous liver resected demonstrated no evidence of steatohepatitis from the irinotecan arterial infusion. Conclusions: Hepatic arterial infusion irinotecan drug-eluting beads is safe and effective in pre-surgical therapy and helpful in evaluating the biology of metastatic colorectal cancer to the liver prior to planned hepatic resection.

Citovat

BOWER, M.; T. METZGER; K. ROBBINS; D. TOMALTY; Vlastimil VÁLEK; Jaroslav BOUDNÝ; Tomáš ANDRAŠINA; C. TATUM a RC. MARTIN. Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study. HPB (Oxford). 2010, roč. 12,2010, č. 1, s. 31-36, 5 s. ISSN 1365-182X. Dostupné z: https://doi.org/10.1111/j.1477-2574.2009.00117.x.

@article{896289,
   author = {Bower, M. and Metzger, T. and Robbins, K. and Tomalty, D. and Válek, Vlastimil and Boudný, Jaroslav and Andrašina, Tomáš and Tatum, C. and Martin, RC.},
   article_number = {1},
   doi = {https://doi.org/10.1111/j.1477-2574.2009.00117.x},
   keywords = {metastatic colon cancer; liver directed therapy; chemoembolization; irinotecan},
   language = {eng},
   issn = {1365-182X},
   journal = {HPB (Oxford)},
   title = {Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study},
   volume = {12,2010},
   year = {2010}
}

TY  - JOUR
ID  - 896289
AU  - Bower, M. - Metzger, T. - Robbins, K. - Tomalty, D. - Válek, Vlastimil - Boudný, Jaroslav - Andrašina, Tomáš - Tatum, C. - Martin, RC.
PY  - 2010
TI  - Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study
JF  - HPB (Oxford)
VL  - 12,2010
IS  - 1
SP  - 31-36
EP  - 31-36
SN  - 1365182X
KW  - metastatic colon cancer
KW  - liver directed therapy
KW  - chemoembolization
KW  - irinotecan
N2  - Background: Neoadjuvant chemotherapy for potentially resectable metastatic colorectal cancer (MCC) is becoming a more common treatment algorithm. The aim of the present study was to evaluate the efficacy of precision hepatic arterial Irinotecan therapy in unresectable MCC. Methods: An open-label, multi-centre, multi-national single arm study of MCC patients, who received hepatic arterial irinotecan. Primary endpoints were safety, tolerance and metastatic tumour resection. Results: Fifty-five patients with metastatic colorectal to the liver underwent a total of 90 hepatic arterial irinotecan treatments. The extent of liver involvement was <25% in 75% of the patients (n = 41), between 26 and 50% in 15% of the patients (n = 11) and >50% in 10% of the patients (n = 24). The median number of hepatic lesions was four (range 1-20), with a median total size of all target lesions of 9 cm (range 5.5-28 cm) with 50% of patients having bilobar tumour distribution. The median number of irinotecan treatments was two (range 1-5). The median treatment dose was 100 mg (range 100-200) with a median total hepatic treatment of 200 mg (range 200-650). The majority of treatments (86%) were performed as lobar infusion treatments, and 30% of patients were treated with concurrent simultaneous chemotherapy. Eleven (20%) patients demonstrated significant response and downstage of their disease or demonstrated stable disease without extra-hepatic disease progression allowing resection, ablation or resection and ablation. There were no post-operative deaths. Post-operative complications morbidity occurred in 18% of patients, with none of them hepatic related. Non-tumorous liver resected demonstrated no evidence of steatohepatitis from the irinotecan arterial infusion. Conclusions: Hepatic arterial infusion irinotecan drug-eluting beads is safe and effective in pre-surgical therapy and helpful in evaluating the biology of metastatic colorectal cancer to the liver prior to planned hepatic resection.
ER  -

BOWER, M.; T. METZGER; K. ROBBINS; D. TOMALTY; Vlastimil VÁLEK; Jaroslav BOUDNÝ; Tomáš ANDRAŠINA; C. TATUM a RC. MARTIN. Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study. \textit{HPB (Oxford)}. 2010, roč.~12,2010, č.~1, s.~31-36, 5 s. ISSN~1365-182X. Dostupné z: https://doi.org/10.1111/j.1477-2574.2009.00117.x.

Přehled o publikaci